当地时间1月7日,强生公司发布消息称,在一项头对头的对照试验中,强生的一款已经获批的肿瘤联合药物与阿斯利康的畅销药奥希替尼(商品名:泰瑞沙)相比,能显著延长非小细胞肺癌(NSCLC)患者生存期。强生公司的这款抗癌药物由Rybrevant和lazertinib组合而成,于2024年8月获得美国FDA批准,用于治疗非小细胞肺癌。非小细胞肺癌是一种常见的肺癌类型。但强生公司没有官方披露该疗法具体能延长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.